Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis

Lobo, Laila; Yakoub, Danny; Picado, Omar; Ripat, Caroline; Pendola, Fiorella; Sharma, R.; ElTawil, Rana; Kwon, Deukwoo; Venkat, Shree; Portelance, Loraine; Yechieli, Raphael

doi:10.1007/s00270-016-1426-y

Cited by 100 publications

(120 citation statements)

References 39 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Moreover, although not explicitly stated, a 3‐year survival time is usually defaulted to be an important watershed for the prognosis of unresectable HCC patients treated with TACE. And, many previous studies utilized “3 year” as an important time point to report the accordingly survival rate in HCC patients treated with TACE . Therefore, based on the previous studies and data in the current study, we considered “3 years” as a reasonable (clinically, statistically, and empirically) cutoff value indicating the long‐term survival in HCC patients undergoing TACE.…”

Section: Discussionmentioning

confidence: 98%

Clinical conditions and treatment requirements for long‐term survival among hepatitis B‐related hepatocellular carcinoma initially treated with chemoembolization

Chen

Jian

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Objective Transarterial chemoembolization (TACE) is recommended to treat intermediate/advanced stage of hepatocellular carcinoma (HCC). However, the overall survival among initially TACE‐treated patients varies significantly. The clinical characterization of long‐term survival following TACE remains uncertain. We sought to identify clinical parameters and treatment requirements for long‐term survival among patients with hepatitis B‐related HCC who were initially treated with TACE. Materials and Methods The included patients with HCC were admitted to our cancer center between December 2009 and May 2015. Patients who survived for >3 years were compared with those who died within 3 years. The clinical and laboratory findings that were associated with the survival were also analyzed. Results One in six (17.9%) patients with HCC in this cohort survived for > 3 years after TACE. Body mass index (BMI) ≥ 23kg/m 2 , aspartate aminotransferase levels ≤ 40 U/L, an activated partial thromboplastin time ≤ 34 seconds, α‐fetoprotein (AFP) levels ≤ 25 ng/mL, antiviral therapy, tumor size ≤ 8 cm, solitary nodule, and the absence of vascular invasion were independently favorably associated with a 3‐year survival. An absence of vascular invasion was the only independent factor associated with 3‐year survival in patients who received resection and/or ablation after TACE. Conclusion In this cohort, a 3‐year survival was associated with BMI, antivirus treatment, tumor status, hepatic function, and AFP level. Distant metastasis did not negatively impact the long‐term survival among patients with hepatitis B‐related HCC initially treated with TACE. Vascular invasion was the single impediment to long‐term survival in patients who received add‐on resection and/or ablation after TACE.

show abstract

Section: Discussionmentioning

confidence: 98%

Clinical conditions and treatment requirements for long‐term survival among hepatitis B‐related hepatocellular carcinoma initially treated with chemoembolization

Chen

Jian

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…However, when PVT or risk of ischemia is present TARE, PEI, or IRE are preferred modalities. These modalities are also limited by their availability, high cost, and operator experience …”

Section: Discussionmentioning

confidence: 99%

Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta‐analysis

Moran

Ramos

Picado

et al. 2018

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) has a recurrence rate of up to 70% in 5 years after resection, detrimentally lowering survival. The role of adjuvant therapy remains controversial; therefore, the aim of this study was to evaluate the disease‐free and overall survival of patients with HCC, not candidates for transplantation, undergoing resection and adjuvant hepatic artery infusion therapy vs resection alone. Our meta‐analysis showed that adjuvant HAIC improves overall and disease‐free survival after resection, especially in tumors ≥7 cm.

show abstract

“…The patient treated with TACE needs at least one day of hospital stay, while TARE is an outpatient procedure. 154 In another meta-analysis by Zhang Y et al, different results were observed. They believed that TARE with Yttrium-90 had better OS, TTP and lower hospitalization time over TACE .…”

Section: Chemotherapy and Radiotherapymentioning

confidence: 97%

New modalities of treatment for hepatocellular carcinoma

Behnagh

Rezaei

Jahannia

et al. 2017

J. contemp. med. sci.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer worldwide. Managing HCC is difficult. However, there are many treatment options available such as liver transplantation, radiotherapy, different ablative techniques, surgery, trans-arterial chemoembolization (TACE) and systemic therapy. These treatments did not show the promising responses and the recurrence rate is still high. On the other hand, there are some new treatments such as immunotherapy, gene therapy, combination of different therapies, Chinese traditional therapies and new targeted therapies. The aim of this study is to review both the recent changes in the common therapies and newly developed therapies of HCC.

show abstract

Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis

Abstract: TARE appears to be a safe alternative treatment to TACE with comparable complication profile and survival rates. Larger prospective randomized trials, focusing on patient-reported outcomes and cost-benefit analysis are required to consolidate these results.

Cited by 100 publications

References 39 publications

Clinical conditions and treatment requirements for long‐term survival among hepatitis B‐related hepatocellular carcinoma initially treated with chemoembolization

Clinical conditions and treatment requirements for long‐term survival among hepatitis B‐related hepatocellular carcinoma initially treated with chemoembolization

Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta‐analysis

New modalities of treatment for hepatocellular carcinoma

Contact Info

Product

Resources

About